Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the worldwide launch of its proprietary Tri-Staple™ technology platform for endoscopic stapling. The...
The Solitaire(TM) FR revascularization device has been cleared by the US Food and Drug Administration and is intended to restore blood flow to the brain...
Representatives from Covidien talk about their Pipeline embolization device and what this innovative new technology means for those suffering from brain aneurysms. Innovations like these...
Prof. Thomas J. Vogl from Joh. Wolfgang Goethe Universität in Frankfurt am Main comments on a percutaneous microwave ablation of a lung metastasis under fluoroscopic...
4-27-12-Covidien (NYSE:COV) reported fiscal Q2 EPS of $1.05, topping estimates by $0.02. Revenues in the quarter rose 5.2% year-over-year to $2.95 billion, inline with estimates....